1178 related articles for article (PubMed ID: 26501517)
1. Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements.
Thakore PI; D'Ippolito AM; Song L; Safi A; Shivakumar NK; Kabadi AM; Reddy TE; Crawford GE; Gersbach CA
Nat Methods; 2015 Dec; 12(12):1143-9. PubMed ID: 26501517
[TBL] [Abstract][Full Text] [Related]
2. CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome.
Klann TS; Black JB; Chellappan M; Safi A; Song L; Hilton IB; Crawford GE; Reddy TE; Gersbach CA
Nat Biotechnol; 2017 Jun; 35(6):561-568. PubMed ID: 28369033
[TBL] [Abstract][Full Text] [Related]
3. An efficient KRAB domain for CRISPRi applications in human cells.
Alerasool N; Segal D; Lee H; Taipale M
Nat Methods; 2020 Nov; 17(11):1093-1096. PubMed ID: 33020655
[TBL] [Abstract][Full Text] [Related]
4. Temporal and Spatial Epigenome Editing Allows Precise Gene Regulation in Mammalian Cells.
Kuscu C; Mammadov R; Czikora A; Unlu H; Tufan T; Fischer NL; Arslan S; Bekiranov S; Kanemaki M; Adli M
J Mol Biol; 2019 Jan; 431(1):111-121. PubMed ID: 30098338
[TBL] [Abstract][Full Text] [Related]
5. Genome and epigenome engineering CRISPR toolkit for
Williams RM; Senanayake U; Artibani M; Taylor G; Wells D; Ahmed AA; Sauka-Spengler T
Development; 2018 Feb; 145(4):. PubMed ID: 29386245
[TBL] [Abstract][Full Text] [Related]
6. Ezh2-dCas9 and KRAB-dCas9 enable engineering of epigenetic memory in a context-dependent manner.
O'Geen H; Bates SL; Carter SS; Nisson KA; Halmai J; Fink KD; Rhie SK; Farnham PJ; Segal DJ
Epigenetics Chromatin; 2019 May; 12(1):26. PubMed ID: 31053162
[TBL] [Abstract][Full Text] [Related]
7. Targeted Chromatinization and Repression of HIV-1 Provirus Transcription with Repurposed CRISPR/Cas9.
Olson A; Basukala B; Lee S; Gagne M; Wong WW; Henderson AJ
Viruses; 2020 Oct; 12(10):. PubMed ID: 33053801
[TBL] [Abstract][Full Text] [Related]
8. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.
Hilton IB; D'Ippolito AM; Vockley CM; Thakore PI; Crawford GE; Reddy TE; Gersbach CA
Nat Biotechnol; 2015 May; 33(5):510-7. PubMed ID: 25849900
[TBL] [Abstract][Full Text] [Related]
9. Establishment of Cell Lines Stably Expressing dCas9-Fusions to Address Kinetics of Epigenetic Editing.
Goubert D; Koncz M; Kiss A; Rots MG
Methods Mol Biol; 2018; 1767():395-415. PubMed ID: 29524148
[TBL] [Abstract][Full Text] [Related]
10. Epigenome editing of the CFTR-locus for treatment of cystic fibrosis.
Kabadi AM; Machlin L; Dalal N; Lee RE; McDowell I; Shah NN; Drowley L; Randell SH; Reddy TE
J Cyst Fibros; 2022 Jan; 21(1):164-171. PubMed ID: 34049825
[TBL] [Abstract][Full Text] [Related]
11. Interrogation of enhancer function by enhancer-targeting CRISPR epigenetic editing.
Li K; Liu Y; Cao H; Zhang Y; Gu Z; Liu X; Yu A; Kaphle P; Dickerson KE; Ni M; Xu J
Nat Commun; 2020 Jan; 11(1):485. PubMed ID: 31980609
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of sgRNA target sites for CRISPR-mediated repression of TP53.
Lawhorn IE; Ferreira JP; Wang CL
PLoS One; 2014; 9(11):e113232. PubMed ID: 25398078
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional repression of PTEN in neural cells using CRISPR/dCas9 epigenetic editing.
Moses C; Hodgetts SI; Nugent F; Ben-Ary G; Park KK; Blancafort P; Harvey AR
Sci Rep; 2020 Jul; 10(1):11393. PubMed ID: 32647121
[TBL] [Abstract][Full Text] [Related]
14. Generation and validation of versatile inducible CRISPRi embryonic stem cell and mouse model.
Li R; Xia X; Wang X; Sun X; Dai Z; Huo D; Zheng H; Xiong H; He A; Wu X
PLoS Biol; 2020 Nov; 18(11):e3000749. PubMed ID: 33253175
[TBL] [Abstract][Full Text] [Related]
15. Targeted Modification of Epigenetic Marks Using CRISPR/dCas9-SunTag-Based Modular Epigenetic Toolkit.
Song MK; Kim YS
Methods Mol Biol; 2024; 2761():81-91. PubMed ID: 38427231
[TBL] [Abstract][Full Text] [Related]
16. Using an Inducible CRISPR-dCas9-KRAB Effector System to Dissect Transcriptional Regulation in Human Embryonic Stem Cells.
Parsi KM; Hennessy E; Kearns N; Maehr R
Methods Mol Biol; 2017; 1507():221-233. PubMed ID: 27832543
[TBL] [Abstract][Full Text] [Related]
17. All-in-One CRISPR-Cas9/FokI-dCas9 Vector-Mediated Multiplex Genome Engineering in Cultured Cells.
Sakuma T; Sakamoto T; Yamamoto T
Methods Mol Biol; 2017; 1498():41-56. PubMed ID: 27709568
[TBL] [Abstract][Full Text] [Related]
18. Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells.
Okada M; Kanamori M; Someya K; Nakatsukasa H; Yoshimura A
Epigenetics Chromatin; 2017; 10():24. PubMed ID: 28503202
[TBL] [Abstract][Full Text] [Related]
19. Mitigation of off-target toxicity in CRISPR-Cas9 screens for essential non-coding elements.
Tycko J; Wainberg M; Marinov GK; Ursu O; Hess GT; Ego BK; Aradhana ; Li A; Truong A; Trevino AE; Spees K; Yao D; Kaplow IM; Greenside PG; Morgens DW; Phanstiel DH; Snyder MP; Bintu L; Greenleaf WJ; Kundaje A; Bassik MC
Nat Commun; 2019 Sep; 10(1):4063. PubMed ID: 31492858
[TBL] [Abstract][Full Text] [Related]
20. Regenerating Urethral Striated Muscle by CRISPRi/dCas9-KRAB-Mediated Myostatin Silencing for Obesity-Associated Stress Urinary Incontinence.
Yuan H; Ruan Y; Tan Y; Reed-Maldonado AB; Chen Y; Zhao D; Wang Z; Zhou F; Peng D; Banie L; Wang G; Liu J; Lin G; Qi LS; Lue TF
CRISPR J; 2020 Dec; 3(6):562-572. PubMed ID: 33346712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
